Chongqing Zhifei Biological Products Co (300122.SZ) Stock Price

Chongqing Zhifei Biological Products Co Price

🇨🇳SZSE·CLOSED
12.45CNY
Market closed
Today +/-
Today %

Chongqing Zhifei Biological Products Co (300122.SZ) Stock | ISIN CNE100000V20. The current Chongqing Zhifei Biological Products Co stock price is 12.45 CNY (2026). Revenue is 11.62 B CNY. Net income is -178.42 M CNY. The P/E ratio is -167.14. Market capitalization is 29.82 B CNY. Chongqing Zhifei Biological Products Co operates in the Health sector.

Over the last 17 years Chongqing Zhifei Biological Products Co grew revenue by 26.3% annually, reaching 26.07 B CNY. Earnings per share have declined at 15.2% per year over the last 17 years. For Chongqing Zhifei Biological Products Co, the net margin of 7.7% is down versus 21.7% a few years ago. At today's price the dividend yield works out to roughly 8.03%. The payout ratio is around 12% of earnings. The dividend has grown at 13.2% per year over the past 13 years.

Chongqing Zhifei Biological Products Co stock price

Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Chongqing Zhifei Biological Products Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Chongqing Zhifei Biological Products Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Chongqing Zhifei Biological Products Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Chongqing Zhifei Biological Products Co Stock Price History
DateChongqing Zhifei Biological Products Co Price
Access this data via the Eulerpool API
Get Free API Key

Chongqing Zhifei Biological Products Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2007
492 M CNY
180 M CNY
152 M CNY
Jan 1, 2008
590 M CNY
221 M CNY
190 M CNY
Jan 1, 2009
604 M CNY
257 M CNY
232 M CNY
Jan 1, 2010
737 M CNY
288 M CNY
257 M CNY
Jan 1, 2011
629 M CNY
155 M CNY
196 M CNY
Jan 1, 2012
760 M CNY
180 M CNY
215 M CNY
Jan 1, 2013
780 M CNY
123 M CNY
130 M CNY
Jan 1, 2014
801 M CNY
148 M CNY
148 M CNY
Jan 1, 2015
713 M CNY
191 M CNY
197 M CNY
Jan 1, 2016
446 M CNY
11 M CNY
33 M CNY
Jan 1, 2017
1.34 B CNY
500 M CNY
432 M CNY
Jan 1, 2018
5.23 B CNY
1.72 B CNY
1.45 B CNY
Jan 1, 2019
10.59 B CNY
2.88 B CNY
2.37 B CNY
Jan 1, 2020
15.19 B CNY
4.02 B CNY
3.3 B CNY
Jan 1, 2021
30.65 B CNY
12.01 B CNY
10.21 B CNY

Chongqing Zhifei Biological Products Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 19, 2026, 6:24 AM
 
REVENUE (B CNY)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B CNY)
NET INCOME (B CNY)
NET INCOME GROWTH (%)
DIV. (CNY)
DIV. GROWTH (%)
SHARES (B)
DOCUMENTS
202020212022202320242025e2026e2027e
15.1930.6538.2652.9226.0710.9311.6211.99
43.48101.7924.8338.29-50.74-58.076.293.16
38.6848.7333.3426.3327.2364.9361.0959.22
5.8814.9412.7613.937.17.17.17.1
3.310.217.548.072.02-1.1-0.181
39.52209.24-26.157.03-74.99-154.46-83.8-661.8
0.50.50.60.331--0.05
––20-45203.03–––
1.62.42.42.42.42.42.42.4
––––––––
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Chongqing Zhifei Biological Products Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Chongqing Zhifei Biological Products Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Chongqing Zhifei Biological Products Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Chongqing Zhifei Biological Products Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Chongqing Zhifei Biological Products Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Chongqing Zhifei Biological Products Co stock margins

The Chongqing Zhifei Biological Products Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Chongqing Zhifei Biological Products Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Chongqing Zhifei Biological Products Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2007
56.5 %
36.59 %
30.89 %
Jan 1, 2008
62.03 %
37.46 %
32.2 %
Jan 1, 2009
67.22 %
42.55 %
38.41 %
Jan 1, 2010
62.01 %
39.08 %
34.87 %
Jan 1, 2011
58.66 %
24.64 %
31.16 %
Jan 1, 2012
55.39 %
23.68 %
28.29 %
Jan 1, 2013
56.41 %
15.77 %
16.67 %
Jan 1, 2014
60.05 %
18.48 %
18.48 %
Jan 1, 2015
79.52 %
26.79 %
27.63 %
Jan 1, 2016
87 %
2.47 %
7.4 %
Jan 1, 2017
76.17 %
37.23 %
32.17 %
Jan 1, 2018
54.51 %
32.94 %
27.75 %
Jan 1, 2019
41.87 %
27.17 %
22.35 %
Jan 1, 2020
38.68 %
26.46 %
21.73 %
Jan 1, 2021
48.73 %
39.18 %
33.3 %

Chongqing Zhifei Biological Products Co Stock Revenue, EBIT, Earnings per Share

The Chongqing Zhifei Biological Products Co earnings per share therefore indicates how much revenue Chongqing Zhifei Biological Products Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2007
44.73 CNY
16.36 CNY
13.82 CNY
Jan 1, 2008
7.38 CNY
2.76 CNY
2.38 CNY
Jan 1, 2009
0.42 CNY
0.18 CNY
0.16 CNY
Jan 1, 2010
0.5 CNY
0.19 CNY
0.17 CNY
Jan 1, 2011
0.39 CNY
0.1 CNY
0.12 CNY
Jan 1, 2012
0.48 CNY
0.11 CNY
0.13 CNY
Jan 1, 2013
0.49 CNY
0.08 CNY
0.08 CNY
Jan 1, 2014
0.5 CNY
0.09 CNY
0.09 CNY
Jan 1, 2015
0.45 CNY
0.12 CNY
0.12 CNY
Jan 1, 2016
0.28 CNY
0.01 CNY
0.02 CNY
Jan 1, 2017
0.84 CNY
0.31 CNY
0.27 CNY
Jan 1, 2018
3.27 CNY
1.08 CNY
0.91 CNY
Jan 1, 2019
6.62 CNY
1.8 CNY
1.48 CNY
Jan 1, 2020
9.49 CNY
2.51 CNY
2.06 CNY
Jan 1, 2021
12.77 CNY
5 CNY
4.25 CNY

Chongqing Zhifei Biological Products Co business model & stock analysis

Chongqing Zhifei Biological Products Co Ltd is a Chinese company that was founded in 1998 and is headquartered in Chongqing, China. The company operates in the biotechnology sector and focuses on the research, development, and manufacturing of biological products. The company initially started in the 1990s as a small laboratory unit of Chongqing Lummy Pharmaceutical Co Ltd, a Chinese pharmaceutical company that mainly produced drugs. In 1998, the company decided to focus on the business of biological products and established Chongqing Zhifei Biological Products Co Ltd. The company's business model is based on the production of high-quality biopharmaceuticals and medical devices. Zhifei Biological Products offers a wide range of products such as vaccines, blood products, virus tests, medical devices, and diagnostic kits. The company has four main business fields: vaccines, blood products, test kits, and medical devices. Among vaccines, Zhifei Biological Products offers a range of vaccines for the prevention of infectious diseases such as hepatitis B, diphtheria, tetanus, and pertussis. The blood products manufactured by the company include intravenous immunoglobulins, plasma proteins, and albumin. Test kits include IgG antibody tests and quantitative PCR tests. Additionally, the company also offers a wide range of medical devices including blood collection kits, syringes, and infusion sets. The company has established itself in China as a trusted and reliable manufacturer of biopharmaceuticals and collaborates closely with various healthcare organizations to promote the prevention and control of infectious diseases. Zhifei Biological Products has also successfully exported its products to other countries and is active in the international market. In recent years, Zhifei Biological Products has also played a crucial role in the fight against the COVID-19 pandemic. The company, in collaboration with the Chinese military, developed and produced a COVID-19 vaccine in a short period of time. This vaccine has already been approved in countries such as Indonesia and Brazil and is being distributed worldwide. The company takes pride in not only manufacturing biopharmaceuticals but also contributing to creating a better world. It has a strong corporate culture and constantly promotes innovation and advanced technology. Chongqing Zhifei Biological Products Co Ltd is a key player in the Chinese biotechnology industry and plays an important role in improving global health.

Chongqing Zhifei Biological Products Co SWOT Analysis

Strengths

Chongqing Zhifei Biological Products Co Ltd has several key strengths that contribute to its success:

  • Strong product portfolio: The company offers a wide range of biological products, allowing it to diversify its revenue streams and cater to different market segments.
  • Advanced research and development capabilities: Chongqing Zhifei invests heavily in R&D, enabling it to develop innovative and high-quality products.
  • Established market presence: The company has a strong market position in the biological products industry, with a well-recognized brand and a large customer base.
  • Robust distribution network: Chongqing Zhifei has built a strong distribution network, ensuring efficient product delivery to customers across China and internationally.
  • Strong financial performance: The company has consistently achieved strong financial results, demonstrating its ability to generate profits and sustain growth.

Weaknesses

Despite its strengths, Chongqing Zhifei Biological Products Co Ltd also faces certain weaknesses:

  • Dependence on a single market: The company heavily relies on the Chinese market, leaving it vulnerable to economic downturns or regulatory changes in the country.
  • Limited global presence: While the company has started expanding internationally, its global presence is relatively limited compared to some of its competitors.
  • Long product development cycle: Developing and gaining regulatory approval for new products can be a lengthy process, potentially slowing down the company's ability to introduce innovations to the market.

Opportunities

Chongqing Zhifei Biological Products Co Ltd can capitalize on the following opportunities:

  • Increasing demand for biological products: The growing adoption of biological products in the healthcare industry presents a significant opportunity for the company to expand its market share.
  • International market expansion: The company can further expand its global presence by entering new markets and forging strategic partnerships with local distributors or healthcare providers.
  • Technological advancements: Rapid advancements in biotechnology and related fields provide opportunities for Chongqing Zhifei to develop and launch innovative products that address unmet medical needs.
  • Government support: Supportive government policies and initiatives aimed at promoting the healthcare industry can create a favorable business environment for the company to thrive.

Threats

Chongqing Zhifei Biological Products Co Ltd should be aware of the following threats:

  • Intense competition: The company operates in a highly competitive market, facing competition from both domestic and international players, which could potentially impact its market share and profitability.
  • Regulatory challenges: Compliance with complex and evolving regulatory requirements in the biopharmaceutical industry can be a challenge, as non-compliance may result in delays or restrictions on product approvals.
  • Economic uncertainties: Adverse economic conditions or unforeseen events, such as the current COVID-19 pandemic, may impact consumer spending on healthcare products and services.

Chongqing Zhifei Biological Products Co Eulerpool Fair Value

Chongqing Zhifei Biological Products Co historical P/E ratio, EBIT multiple, and P/S ratio

Chongqing Zhifei Biological Products Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Chongqing Zhifei Biological Products Co shares outstanding

The number of shares was Chongqing Zhifei Biological Products Co in 2025 — This indicates how many shares 2.395 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2007
11 M base_Shares
Jan 1, 2008
80 M base_Shares
Jan 1, 2009
1.44 B base_Shares
Jan 1, 2010
1.48 B base_Shares
Jan 1, 2011
1.6 B base_Shares
Jan 1, 2012
1.6 B base_Shares
Jan 1, 2013
1.6 B base_Shares
Jan 1, 2014
1.6 B base_Shares
Jan 1, 2015
1.6 B base_Shares
Jan 1, 2016
1.6 B base_Shares
Jan 1, 2017
1.6 B base_Shares
Jan 1, 2018
1.6 B base_Shares
Jan 1, 2019
1.6 B base_Shares
Jan 1, 2020
1.6 B base_Shares
Jan 1, 2021
2.4 B base_Shares

Chongqing Zhifei Biological Products Co Dividend History

14 years of dividend payments

YearAnnual DividendYoY ChangePayments
20241CNY↑ 200.0%2×
20230.33CNY↓ 44.4%1×
20220.6CNY↑ 20.0%1×
20210.5CNY 0.0%1×
20200.5CNY 0.0%1×
20190.5CNY↑ 284.6%1×
20180.13CNY↑ 1200.0%1×
20170.01CNY↓ 80.0%1×
20160.05CNY↓ 50.0%1×
20150.1CNY 0.0%1×

Chongqing Zhifei Biological Products Co dividend payout ratio

In 2025, Chongqing Zhifei Biological Products Co had a payout ratio of 12.83%. The payout ratio indicates the percentage of the company's profits that Chongqing Zhifei Biological Products Co distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2007
13.12 %
Jan 1, 2008
13.12 %
Jan 1, 2009
13.12 %
Jan 1, 2010
13.12 %
Jan 1, 2011
29.75 %
Jan 1, 2012
34.31 %
Jan 1, 2013
67 %
Jan 1, 2014
39.67 %
Jan 1, 2015
29.75 %
Jan 1, 2016
178.5 %
Jan 1, 2017
2.63 %
Jan 1, 2018
10.21 %
Jan 1, 2019
24.13 %
Jan 1, 2020
17.33 %
Jan 1, 2021
8.4 %
Price targets and forecasts for Chongqing Zhifei Biological Products Co are not yet available.

EESG©

Eulerpool ESG Scorecard© for the Chongqing Zhifei Biological Products Co stock

88/100
99
Environment
96
Social
70
Governance
E

Environment

20
Scope 1 - Direct Emissions13,575.52
Scope 2 - Indirect emissions from purchased energy76,807.2
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions90,382.72
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees39.39
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Chongqing Zhifei Biological Products Co shareholder structure

% Name
48.41134%
Jiang (Rensheng)
Jiang (Rensheng)
5.4107%
Jiang (Lingfeng)
Jiang (Lingfeng)
3.33991%
Liu (Tieying)
Liu (Tieying)
1.63468%
E Fund Management Co. Ltd.
E Fund Management Co. Ltd.
0.85255%
Huatai-PineBridge Fund Management Co., Ltd.
Huatai-PineBridge Fund Management Co., Ltd.
0.74058%
Wu (Guanjiang)
Wu (Guanjiang)
0.73376%
Shanghai Yingshui Investment Management Co., Ltd.
Shanghai Yingshui Investment Management Co., Ltd.
0.70139%
Jiang (Xisheng)
Jiang (Xisheng)
0.67445%
China Merchants Fund Management Co. Ltd.
China Merchants Fund Management Co. Ltd.
0.59874%
China Asset Management Co., Ltd.
China Asset Management Co., Ltd.
...

Chongqing Zhifei Biological Products Co Executives and Management Board

LD

Mr. Lin Du

(59)

Director

Compensation1.6 M CNY
SY

Mr. Shilong Yang

(41)

Director

Compensation1.6 M CNY
ZL

Mr. Zhenjing Li

(42)

Chief Financial Officer, Vice President, Director · since 2015

Compensation1.4 M CNY
XJ

Mr. Xisheng Jiang

(64)

Vice President

Compensation1.4 M CNY
HS

Mr. Haitian Sun

(46)

Vice President

Compensation1.4 M CNY

Frequently asked questions about Chongqing Zhifei Biological Products Co

The business model of Chongqing Zhifei Biological Products Co Ltd revolves around the development, production, and sales of vaccines and biological products. As a leading biotech company in China, Chongqing Zhifei focuses on the research and manufacturing of innovative vaccines for infectious diseases. By leveraging advanced technology and scientific expertise, the company aims to meet the increasing global demand for high-quality vaccines. Chongqing Zhifei is committed to providing effective immunization solutions to improve public health, ensuring their products adhere to stringent quality standards. With a focus on research and development, production, and market expansion, Chongqing Zhifei's business model is centered on delivering sustainable and life-saving healthcare solutions.

All fundamentals and in-depth analysis of Chongqing Zhifei Biological Products Co

Our stock analysis for Chongqing Zhifei Biological Products Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chongqing Zhifei Biological Products Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co Revenue→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co Net Income→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co P/E→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co P/S→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co EBIT→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co Dividend→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co Directors Dealings→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co Stocks→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co Market capitalization→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co Debt→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co Liabilities→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co Equity→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co AAQS→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co Employees→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co ROE→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co ROA→
Chongqing Zhifei Biological Products Co Stock
Chongqing Zhifei Biological Products Co ROCE→